CHICAGO, IL—Reports of device embolization during the limited market rollout of the next-generation Watchman FLX left atrial appendage closure device in Europe have caused manufacturer Boston ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

Left atrial appendage (LAA) closure with the new-generation Watchman FLX device (Boston Scientific) provides a high rate of effective closure with few early adverse events, according to results of ...

Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

(RTTNews) - Boston Scientific (BSX) said that 24-month results from the PINNACLE FLX clinical trial demonstrated the safety and performance of WATCHMAN FLX left atrial appendage closure device for ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...

In-hospital safety and procedural outcomes for percutaneous left atrial appendage (LAA) closure are substantially better with the Watchman FLX device than with its predecessor, new research shows.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The ...

Boston Scientific (BSX) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

The US Food and Drug Administration (FDA) has approved Boston Scientific's WATCHMAN FLX transcatheter left atrial appendage (LAA) occluder device as an alternative to oral anticoagulation (OAC) ...